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Current and reoccurring viral epidemic outbreaks such as those caused by
the Zika virus illustrate the need for rapid development of antivirals. Such
development would be facilitated by computational approaches that can
provide experimentally testable predictions for possible antiviral strategies.
To this end, we focus here on the fact that viruses are directly dependent
on their host metabolism for reproduction. We develop a stoichiometric,
genome-scale metabolic model that integrates human macrophage cell
metabolism with the biochemical demands arising from virus production
and use it to determine the virus impact on host metabolism and vice
versa. While this approach applies to any host–virus pair, we first apply
it to currently epidemic viruses Chikungunya, Dengue and Zika in this
study. We find that each of these viruses causes specific alterations in the
host metabolic flux towards fulfilling their biochemical demands as pre-
dicted by their genome and capsid structure. Subsequent analysis of this
integrated model allows us to predict a set of host reactions, which, when
constrained, inhibit virus production. We show that this prediction recovers
known targets of existing antiviral drugs, specifically those targeting nucleo-
tide production, while highlighting a set of hitherto unexplored reactions
involving both amino acid and nucleotide metabolic pathways, with either
broad or virus-specific antiviral potential. Thus, this computational
approach allows rapid generation of experimentally testable hypotheses
for novel antiviral targets within a host.1. Introduction
The rapid development of antiviral drugs for emerging and re-emerging
viruses, such as the Zika virus, remains a significant challenge [1,2]. Given
that virus production within a host is intertwined with host immune response
and metabolism [3], it is suggested that new development of antivirals should
take into account host processes [4,5]. Indeed, viruses are entirely dependent on
their hosts’ cellular resources for their replication. This is highlighted
by observed variations in virus production levels correlating with cell-to-cell
variance in growth rate and phase [6], as well as virus infection leading to
changes in host metabolism [7]. In particular, virus infection leads to significant
metabolic alterations in the host, in some cases resulting in up to threefold
increase in glycolysis rates [7–9] and changes in ATP production rates [6].
This observation can be seen as an emergent property of the combined
host–virus metabolic system and could be related to changes in host cellular
demands arising from viral production [10,11]. More specifically, alterations
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viruses actively manipulating the host system to their advan-
tage [12], or the additional draw of metabolic components for
viral production simply resulting in a rearrangement of host
metabolic fluxes.
Regardless of its cause, the entanglement between host
metabolism and viral production opens up the possibility
to perturb the former, as a way of limiting the latter
[9,12,13]. To explore this possibility and towards understand-
ing the potential interplay between host metabolism and the
additional ‘virus demand’ on it, stoichiometric genome-scale
metabolic models and their optimization through flux bal-
ance analysis (FBA) can provide ideal starting points as
they are demonstrated to allow analysis of cellular physi-
ology as an interconnected system [14,15]. Integration of
virus production in a host metabolic model has already
been used to study the infection of bacteria with phage, indi-
cating the presence of metabolic limitations on phage
replication depending on the host’s metabolic environment
[16]. Such studies have shown that while FBA does not
allow for the simulation of a virus infection over time, it pro-
vides valuable insights into the metabolic rearrangements
that occur from an uninfected to infected state [16]. Theoreti-
cally, this type of stoichiometric metabolic analysis can
potentially be applied to any host–virus pair; it is particu-
larly suited to Alpha- and Flavi-viruses. The rather simple
physical and genomic structure of these viruses [17,18]
allows straightforward construction of a pseudo biochemical
reaction representing their production from constituting parts.
This pseudoreaction can then subsequently be incorporated
into a genome-scale metabolic model of any host.
Here, we develop and apply such an FBA approach to
analyse host–virus metabolic entanglement. We focus this
analysis on representatives of the virus genera Alpha-
(CHIKV) and Flavi-virus (DENV, ZIKV), of the Togaviridae
and Flaviviridae virus families, which are positive-sense
single-strand RNA viruses with rather simple physical struc-
tures [17,18]. Viruses of both families have been observed to
infect many different human cell types [19,20], including
monocyte-derived macrophage cell lines [19,21,22], and are
usually transmitted to humans via arthropod vectors, the
most common being mosquitoes of the Aedes genus [23,24].
By analysing the integrated metabolic model, we find that
viral production results in significant alterations in host meta-
bolic fluxes, including changes in central carbon metabolism
and lipid biosynthesis pathways. These changes have led us
to postulate that a set of host reactions can be constrained in
such a way to inhibit virus production. We show that this
approach can indeed allow prediction of key virus-limiting
host reactions, which overlap with known targets of existing
antiviral drugs, such as those targeting host nucleotide path-
ways. In addition, our predictions highlight a set of hitherto
unexplored host reactions as potential antiviral targets.2. Results
To analyse host–virus interaction from a metabolic stance, we
developed here an integrated stoichiometric model of a
human macrophage cell infected with a virus. This integrated
virus–macrophage metabolic modelling approach was con-
sidered here for three viruses causing recent epidemic
outbreaks: Chikungunya virus (CHIKV); Dengue virus(DENV); and Zika virus (ZIKV). For each virus, we integrated
a biomass reaction into the human model that represents the
production of virus particles. While the viral genome and
protein stoichiometry are available for most species of
Alpha- and Flavi-virus genera, the detailed stoichiometric
quantification of their lipid envelopes is mostly lacking
[17,18]. Thus, the presented analysis is based only on the
amino acid and nucleotide requirements constituting the
virus biomass function (see Methods and electronic sup-
plementary material, figure S1 for details of virus biomass
calculations).
2.1. Host metabolism displays alternative host- and
viral-optimal states
We first used the integrated virus–macrophage stoichio-
metric metabolic model to interrogate potential changes
in host metabolism upon virus infection. To do so, we con-
sidered two idealized scenarios: (i) the metabolic system is
optimized for the functional requirements of the host cell
as determined by a maintenance-related biomass reaction
[25] (host-optimal state); (ii) the metabolic system is opti-
mized solely for virus particle production (virus-optimal
state). These two states provide the theoretical extremes
of a continuum of metabolic states that can arise during
virus infection. While the first scenario aims to represent
the normal physiological state of macrophage cells, the
second state represents a thought experiment of the host
metabolic fluxes being set for maximizing virus production
(figure 1a,b).
To compare the host- and virus-optimal states of the
model, we analyse the metabolic fluxes directly feeding into
the biomass pseudoreaction (see electronic supplementary
material, files S1 for biomass reactions and S2 for flux
values and ranges). This is done by analysing the fluxes
that directly produce a given biomass precursor (e.g. alanine)
in both the host- and virus-optimized states. As expected
from linear optimization, we find that the difference in
these fluxes (for the two optimization cases) reflects the stoi-
chiometric differences in the amino acid and nucleotide
requirements of the host cell and the virus, thus achieving
perfect fulfilment of host or virus biomass requirements.
We conclude that stoichiometric differences in metabolic
requirements for virus production versus host maintenance,
as summarized in figure 2, result in different metabolic flux
states of the host model.
2.2. Host- and virus-optimal metabolic states require
non-overlapping flux ranges in vital metabolic
subprocesses
To understand how the flux changes at the biomass level
affect the metabolic system, we calculated the allowed flux
variability for individual reactions in the model using either
host- or virus-based optimization (seeMethods). Flux variabil-
ity analysis (FVA) allows for a more robust analysis of
different states of the model, compared to merely calculating
optimal flux sets, which are shown to be subject to inaccura-
cies inherent in linear solvers used in FBA [26]. We find that
the median of the allowed optimal metabolic flux ranges,
between host- and virus-optimal states, shows significant
changes across different metabolic processes (called
amino acids RNA DNA sugar lipids
macrophage CHIKV DENV ZIKV
3395 reactions|2572 metabolites
(b)
(a)
Figure 1. Comparison of host macrophage and viral biomass compositions, and metabolic. (a) Comparison of host macrophage, CHIKV, DENV and ZIKV biomass
compositions, as described from their respective biomass objective functions, using five different macromolecular classes (amino acids, RNA, DNA, sugar and lipids.
Full breakdown of biomass is available in electronic supplementary material, file S1). (b) Bipartite graph visualization of the macrophage metabolic network, where
nodes are metabolites (white fill) or reactions (grey fill), edges are connections between them and indicate directionality. CHIKV, Chikungunya virus; DENV, Dengue
virus; ZIKV, Zika virus.
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plementary material, file S2). In particular, the virus-optimal
state displays significantly increased median flux for reactions
associated with lipid metabolism and nucleotide biosynthesis
and significantly decreased flux for reactions associated with
unsaturated fatty acid biosynthesis and transport (including
intracellular transport reactions). Besides these general overall
trends across subprocesses, the virus-optimal state displays
also differences in the median flux of specific reactions within
each subprocess (see pie charts in figure 3). These changes are
per downstream requirements for fulfilling biomass require-
ments and relate to interconnections among subprocesses.
For example, reactions showing the most increase from host-
to virus-optimised flux states involveADP/ATPand inorganic
phosphor (Pi), signifying a shift from the lipid-production in
the host-optimal state to phosphate-reclaim in the virus-
optimal state. These metabolites, specifically phosphate andphosphate derivatives in the latter example, link directly into
the reactions of the nucleotide biosynthesis subprocess
(which then feed into increased nucleotide requirement in the
virus, see figure 2).
The specific change in the allowed flux ranges also high-
light potential physiological changes. As an illustrative
example, we show the extent of changes within the glycolysis
pathway, where allowed flux ranges that can sustain virus
optima are wider compared to those that can sustain host
optima (figure 3). The allowed ranges for glucose and
oxygen uptake indicate that virus optima can be sustained
even under low-uptake fluxes, indicative of the potential
feasibility of anaerobic metabolism still sustaining virus pro-
duction [27]. Taken together, this comparison of host- and
virus-optimal states show that the differences within the stoi-
chiometric requirements of the different viruses and the host
cause large-scale alterations in the host metabolic fluxes.
1.5 CHIKV//S27
DENV-2//16681
ZIKV//MR 766
1.0
3.0
2.5
2.0
1.5
1.0
0.5
0
0
0.5
–0.5
–1.0
–1.5
A R N D C Q E G H
amino acids
lo
g 2
 
fo
ld
 c
ha
ng
e
I L K M F P S T W Y V A C
nucleotides
G U
(b)(a)
Figure 2. Fold-change difference in usage of amino acids and nucleotides between host and CHIKV, DENV and ZIKV. (a,b) The usage of amino acids (a) and
nucleotides (b) between the host and virus biomass objective functions. The differential usage was calculated against all biomass precursors. Comparison was
conducted for all 20 amino acids, and four RNA nucleotides (the x-axes are labelled with the standard short notations for these). All calculations and biomass
formulations are as described in the Methods, and all biomass stoichiometric values are provided as electronic supplementary material, file S1.
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and virus-optimal metabolic states match
metabolite-based observations from infected cells
As discussed above, the model predictions up to this point
arise from a thought experiment in which we compare
fluxes from the host metabolic system optimized for either
host maintenance or viral production. While a full shift of
host metabolism to supporting viral production is unlikely,
this comparison can still provide insights into how metabolic
fluxes in a host might shift with virus infection. To see if the
model predictions match with biological observations, we
attempted to compare the general flux results with exper-
imental data collected from controlled virus infection
experiments involving the three viruses studied here. Unfor-
tunately, we did not find any studies that have directly
measured metabolic flux changes during or after infection.
There were, however, few datasets that considered changes
in the cell medium or the serum upon infection, and we
found notable overlaps with these data and predictions. For
example, the model predictions for increased alanine
exchange (’EX_ala(e)’) in the DENV-optimized model were
in line with the observed increase in alanine levels in the
media of DENV2-infected versus -uninfected EA.hy926 cells
[28]. Similarly, the upregulation of glycine, serine and threo-
nine metabolic subprocesses (contained within the ‘amino
acid’ subprocess in figure 3a) in the CHIKV- and DENV-opti-
mized models matches with previous metabolomics studies of
CHIKV- and DENV-infected human serum [29]. In the case of
the ZIKV-infected model, we find that our prediction of the
virus-induced upregulation of dihydrofolate reductase
(DHFR) is in line with previous metabolomics studies of
ZIKV-infected human serum [30].
We also collated gene expression data from several infec-
tion experiments, presenting expression levels before and
after infection (see electronic supplementary material and
file S9). Unfortunately, none of these studies was conductedon the modelled host, the human macrophage cell, but
instead used other human cell lines, and as a result we did
not find a strong overall correlation between expression
changes in metabolic genes and model-based flux changes
(in line with the previously observed lack of correlation
between enzyme expression and metabolic flux changes [31]).2.4. The integrated model highlights enforcement of
host-optimal flux ranges as an antiviral strategy to
suppress viral production
As the host-optimal and virus-optimal flux ranges within
the integrated model differ, we hypothesize that the model
can be constrained in a way to limit viral production
(see Methods). To test and use this hypothesis, we use the
integrated stoichiometric model to identify the host reac-
tions, which, when constrained, limit virus production the
most. This analysis can be implemented in different ways,
for example through constraining of flux values to zero
(i.e. reaction ‘knock-outs’). Applying such knock-outs, we
find several reactions that limit virus optima, but all of
these also result in significant reduction in host optima (elec-
tronic supplementary material, file S3). To identify if there
are any reactions that can perturb virus production, while
maintaining the host viability, we constrained reaction
fluxes to ranges that are derived from the FVA described
above. In particular, we identified flux ranges that still
allowed for the attainment of the host-optimal state but
were outside of the range allowed by the virus-optimal
state (see Methods).
This approach highlights a set of reactions that result in
different levels of reductions in the virus optima of CHIKV,
DENV or ZIKV, while not affecting the host optima (as
expected from the way we set the flux constraints; see
Methods). We identify 29 reactions that can reduce the virus
optima to below a threshold [80%] of the original value for
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Figure 3. Comparison of model fluxes between host optima and CHIKV, DENV and ZIKV optima. (a) Comparisons are visualized as the sum of fluxes over aggregated
subsystems using values from host- and virus-optimal states. Abbreviations used in the subsystem classification are: FAS, fatty acid synthesis; ROS, reactive oxygen
species; UFAS, unsaturated fatty acid synthesis; Misc., miscellaneous. The y-axis represents differential usage of aggregate subsystems, while the colours of the bars
indicate different viruses and host (see colour coding on the panel). Positive and negative values reflect a higher or lower total flux for that subsystem in the virus-
compared to host-optimal state. Pie charts over each bar provide a summary of changes on individual reactions within a subsystem. The complete set of flux values
for all reactions in the model and all optimal states are provided as electronic supplementary material, file S1. (b) Simplified schematic showing reactions involved in
the glycolysis pathway. (c) Corresponding flux ranges of individual reactions in the glycolysis pathway that allow attainment of host and virus optima. The flux
ranges allowing optima for individual viruses, as well as the host, are shown in differentially coloured bars, with the x-axis showing flux values. The colour coding is
as shown in panel a.
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file S4; full results are provided in electronic supplementary
material, file S3). Interestingly, many of these 29 reactions
are interconnected and are involved in the de novo synthesis
of RNA nucleotides (both purine and pyrimidine pathways)
and amino acid interconversions (figure 4). Particular
examples include reactions directly involved in the synthesis
of adenosine, guanosine and uridine/cytidine nucleotides,
and upstream reactions such as those involving inosine
monophosphate (IMP) and orotidine monophosphate
(OMP). We found that these predictions were robust
towards changes in key model assumptions (see electronic
supplementary material).2.5. The predicted antivirals match known ones and
include new host-based antiviral candidates
These identified reactions are potential antiviral targets, in
the sense that altering their fluxes can limit virus production
within the host. Thus, we explored if these reactions match
with known antiviral drug targets. Performing a literature
analysis, we found that there are currently 10 antivirals,
specific to RNA viruses, and that these target only five
unique metabolic enzymes (see electronic supplementary
material, table S1). Of these five drug targets (and the associ-
ated drugs), one has been experimentally verified to be
effective against CHIKV (inositol-50-monophosphate
pentose phosphate
pathway
ribose-5P
a ribose-5P
PRPP
GAR
FGAM
FPRAM
AIR
5AIZC
SAICAR
AICAR
fumurate
FAICAR
IMP XMPdcAMP GMP
carbamoyl-phosphate
glutamine
biosynthesis
aspartate
glutamine
N-carbamoyl aspartate
dihydroorotate
orotate
OMP
UMP
UDP
UTP
CTP
glutamate
PRAM
glycine
HCO3
CO2
aspartate
AMP GDP
isoleucine
lysine
Tyr-ggn
phosphate
H2CO3
HCO3CO2
H2O H+
glycine
serine
intracellular extracellular
M1
V1
M2
M3 M4
M5 biomass
host
virus
e– e+
flux range
(V6)
host
virus
0
V2
V3 V4
V7
V5 V6 [0, 0]
M1
V1
M2
M3 M4
M5 biomass
V2
V3 V4
V5 V6
V7
flux range
(V6)
[e–, e+]
(a) (b)
(c)
Figure 4. Prediction of antiviral targets [reactions] from single-reaction perturbations in a virus-optimized system for CHIKV, DENV and ZIKV. (a) Simplified schematic
for single-reaction knockouts, where flux ranges for a desired reaction flux v are shown for both host- and virus-optimized systems. Square brackets, associated with
specific flux vector indices 1–7, denote the lower (lb) and upper (up) flux bounds ([lb,ub]). Under knockout conditions both lb and ub are set to zero. (b) Simplified
schematic for single-reaction enforcements, where flux ranges for a desired reaction flux v are shown for both host- and virus-optimized systems. Square brackets,
associated with specific flux vector indices 1–7, denote the lower (lb) and upper (up) flux bounds ([lb,ub]). Under host-derived enforcement conditions, lb and ub
are set to e2 and eþ, respectively (see Methods). (c) Reaction pathway schematic showing the top 29 reactions from host-derived flux enforcement analysis and
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ated with subsystems: orange, pyrimidine synthesis; purple, pentose phosphate pathway; blue, purine synthesis; green, nucleotide biosynthesis. The starting
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by a known antiviral or inhibitor are marked by white and red filled stars and circles, respectively. Complete list of antiviral compounds from which the matches were
obtained is provided as electronic supplementary material, table S1. A complete list of inhibitors and the associated reactions is provided as electronic supplementary
material, file S4. A complete list of enforcement results for all reactions is provided as electronic supplementary material, files S2 and S5.
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(dihydroorotate dehydrogenase; DHORD9) [33]. While the
other three targets have been verified to be effective against
some RNA viruses [34], they are yet to be tested against
CHIKV, DENV and ZIKV.
We found that out of these five known antiviral targets,
all are implicated in our analysis. The three known antiviral
target reactions involving the genes IMPD [32]; DHORD9
[33]; and orotidine-50-phosphate decarboxylase (OMPDC)
[34] are found to perturb virus optima for all viruses
(figure 4). The antiviral target S-adenosylhomocysteine
hydrolase (AHC) [34] is predicted to affect only CHIKV
optima and only to a level higher than the 80% cut-off we
used in the above analysis. We note that setting AHC reaction
flux to zero abolishes virus growth for all three viruses (see
electronic supplementary material, file S3). Finally, CTP
synthase, which has been indicated to exhibit an effect on
several RNA viruses [34], is included in the model as two
reactions which perform the same reaction. These are defined
as using either ammonia (mediated by CTPS1) or glutamine
(mediated by CTPS2) as a nitrogen source [35] and therefore
not highlighted in our initial flux enforcement analysis focus-
ing on a single reaction. When we constrain both reactions
associated with these two reactions simultaneously at
host-derived flux ranges, a reduction in all virus optima
is observed.
2.6. Existing drugs can target many of the predicted
additional host reactions affecting virus production
Considering the computationally predicted potential of the
additional reactions identified as antiviral targets, we have
searched for these reactions in a database of known
inhibitor-like compounds [36]. We found that 15 of these
reactions already have known compounds and, in some
cases, existing drugs, targeting their catalysing enzymes,
identified from the DrugBank and BRENDA databases
(figure 4, and full list in electronic supplementary material,
file S4). These findings present experimentally testable pre-
dictions on host reactions, the disruption of which could
limit virus production. It must be noted, however, that our
computational analysis identifies flux enforcement based on
differences in host- and virus-optimal states of the model,
where ‘enforcement’ can mean either reduction or increase
in a given flux. By contrast, most of the currently known mol-
ecules act as enzyme inhibitors [36] and would be expected to
reduce metabolic fluxes. For the reactions highlighted in
figure 4, we find that all reactions are downregulated
(decreased flux) compared to the virus-optimal flux for
that reaction.3. Discussion
We present a computational approach that combines appli-
cation of FBA and FVA with the development of integrated
host–virus metabolic models. We show that this approach
recovers the known metabolic antiviral targets within a
human macrophage cell and predicts new potential targets.
These predicted reactions fall primarily onto pathways invol-
ving nucleotides and amino acids that are differentially used
by the host and virus. The results of this study are in line with
an integrated perspective that views the virus as anadditional metabolic burden on the host cells that could be
met or avoided by tinkering of host metabolic fluxes. The
observed overlap between predicted reactions and known
antiviral drugs gives confidence to this integrated modelling
approach and highlights its potential as a rapid prediction
tool to guide experimental design. This can be especially
useful in the case of new and emerging viruses for which
limited clinical and experimental data may be available to
inform drug target identification.
The integrated stoichiometric metabolic modelling
approach focuses on metabolic changes as a driver of virus
production and does not consider factors associated with
virus–host cell recognition, viral entry, lipid envelope pro-
duction and release [37]. In addition, this approach does
not consider possible additional dynamical transcription pro-
cesses during viral infections, such as sub-genomic particle
generation [38]. These additional mechanisms relating to
the virus infection and production can possibly be incorpor-
ated in future dynamical models. The current application of
the linear optimization on stoichiometric models (i.e. FBA
and FVA) strictly assumes that host metabolism is at steady
state, and thus prohibits analysis of the dynamics of cellular
physiology. Such dynamics could be taken into account to a
certain extent by imposing different flux constraints, which
could be derived from proximal experimental data [16],
through the development of simplified metabolic temporal
models [10,11], or by combining dynamics with linear optim-
ization on stoichiometric models [39,40]. Additionally, the
extent of the missing information, such as genes, enzymes
or reactions, in genome-scale stoichiometric models creates
limitations on how much of the metabolic processes can be
covered [41].
Future efforts to improving model curation and standard-
ization [42] would open up the possibility of extensive
analysis of host–virus pairings from a metabolic stance.
Such modelling efforts would immensely benefit from a
collection of appropriate, relevant experiment datasets. In
particular, experimental analysis of cellular metabolic
fluxes, as well as the determination of cellular uptake rates
and metabolite requirements, can allow direct evaluation of
the model. The presented findings already suggest that inte-
grated host–virus models can highlight metabolic changes in
the host and predict principal host metabolic processes that
are linked to host–virus compositional mismatches and that
can be used to combat virus production without altering
host functions. In particular, analysis of extended flux enfor-
cement strategies such as flux limitations on double and triple
reaction combinations might identify virus-specific drug
combinations. Combining this with the future development
of additional host–virus integrated models, covering many
cell and virus types, can thus allow a fruitful route to the
computational guiding of experimental antiviral drug
discovery.4. Methods
4.1. Flux balance analysis
FBA is a mathematical, constraint-based modelling method used
to simulate reconstructions of cellular metabolic networks [43].
FBA assumes that the metabolic model is at steady state, and
uses linear optimization to predict a set of fluxes that is compa-
tible with this assumption and the enforced upper and lower flux
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different biologically relevant objective functions can be con-
structed, a commonly employed one involves a pseudoreaction
representing cellular biomass production or maintenance. The
linear optimization problem used in FBA can be generally
formalized as follows:
maximise Z ¼ cTv
subject to Sv ¼ 0
lbi  vi  ubi
where S is the stoichiometric matrix, defining the stoichiometry
of metabolites in different reactions, v is a vector of metabolic
reaction fluxes, and c is a vector of the same size as v and encod-
ing the objective function Z (e.g. c might be a binary vector with
1 at the index of the reaction(s) composing the desired objective,
and 0 elsewhere). Additional constraints on each reaction flux vi,
is defined through the minimal (lb) and maximal (ub) flux
bounds.
Here, we implement FBA and its close variant FVA for
specific analyses of an integrated host–virus metabolic model
as described in further detail below. FVA provides an additional
layer of information to FBA by predicting the permissible flux
values for each reaction. Thus, FVA yields two flux distribution
vectors, which predict the minimum and maximum flux value
that a reaction can have (defined as its flux range) given the
objective function.
4.2. Generation of virus biomass objective functions
To implement the FBA approach to studying virus infections
from a metabolic stance, we define a pseudoreaction accounting
for the production of virus particles from its constituents. We call
this reaction a virus biomass objective function (VBOF). To
account for metabolic fluxes associated with the virus pro-
duction, the VBOF needs to capture the stoichiometry of
nucleotide, amino acid and associated energy metabolites relat-
ing to virus production, similar to biomass production function
used for microbial metabolic models [44]. We derive the meta-
bolic stoichiometry of virus production from the viral genome
sequence, the subsequently encoded proteins, the copy number
of those proteins, and knowledge of the energetic requirements
for peptide bonds and phosphodiester bonds. As previously
mentioned, we do not include the virus envelope in the VBOF
due to a lack of stoichiometric information regarding virus-
associated lipids. We also do not include lipids due to the lack
of dynamics in the model (therefore virus entry/exit is not mod-
elled, where the exit is the location of virus envelope acquisition).
Details of the VBOF derivation are given below, while a
schematic of VBOF generation is included as electronic
supplementary material, figure S1.
4.2.1. Genome and protein information for the viruses
The genome sequences used in the present study are obtained
from the NCBI genomic database [45] using the following acces-
sion numbers and accessed in March 2016; ZIKV: NC_012532.1,
DENV: NC_001474.2, and CHIKV: NC_004162.2 (original files
are provided on the Soyer group research website: http://
osslab.lifesci.warwick.ac.uk/?pid=resources). Viruses can be
classified by their replication methods, known as the Baltimore
Classification System [46], and depending on this classification,
a viral particle may contain more than a single copy of the
genome. This is factored into the calculation of the nucleotide
counts. In the presented study, all studied viruses fall into
Group IV classification: they replicate their positive single-
stranded RNA (þssRNA) genome via a negative ssRNA
(2ssRNA) intermediate. Therefore, the counts of the nucleotides
in the negative strand is equal to the counts of the complemen-
tary nucleotide in the positive strand, i.e. count of A on (þ/2)strand ¼ count of U on (2/þ) strand, and similarly for G and
C counts. The count for each RNA nucleotide (adenosine (A),
cytidine (C), guanine (G) and uracil (U)) can be taken directly
from the virus genome sequence: RNA uses U in place of
thymine (T); therefore, T must be replaced with U from the
genome sequence read-out. In this study, all the viruses have
two categories of polyproteins that compose the proteome:
structural and non-structural. The amino acid sequence of these
two polyproteins, and indeed any genome-derived protein
sequences, are obtained from gene annotations of the viral
genomes as provided in the NCBI genome entries (see above
for NCBI entries used). The different subcategories of the viral
proteome may be differentially incorporated into a single virus
particle. For the viruses studied here, the structural and non-
structural polyproteins are expressed in a ratio that is derived
from the overall virus structure (i.e. proteins in the capsid or
nucleocapsid) [18]. The ratio is 1 : 240 for CHIKV [18], and 1 :
180 for DENV/ZIKV [17]. More broadly, the ratio of different
protein classes in a single virus particle can be derived from
the overall virus structure or directly from literature/experimental
evidence.4.2.2. Calculating nucleotide investment per virus
The total moles of each nucleotide in a mole of virus particle
ðNTOTi Þ are obtained from their count in the virus genome ðNGi Þ
and replication intermediates ðNRi Þ, and multiplied by the
genome copy number (Cg):
NTOTi ¼ Cg(NGi þNRi ), ð4:1Þ
where the indexation is over nucleotides. The moles of nucleo-
tides are then converted into grams of nucleotide per mole of
virus (gNTPS mol
1
virus; G
N
i ), by multiplying N
TOT
i with the respective
molar mass (g mol21) of the nucleotides ðMNi Þ:
GNi ¼ NTOTi MNi , ð4:2Þ
where the indexation is over nucleotides. Summing GNi over all
nucleotides and combining this with the similar calculation for
amino acids allows us to get the total molar weight of the virus
regarding nucleotides and amino acids (Mv; see equation (4.15)
below). Finally, the stoichiometric coefficients of each nucleotide
in the VBOF are expressed as millimoles per gram of virus
(mmolNTPS g1virus; S
N
i ):
SNi ¼ 1000
NTOTi
Mv
 
, ð4:3Þ
where the indexation is over nucleotides.4.2.3. Calculating amino acid investment per virus
The total moles of each amino acid per mole of virus particle
ðXTOTj Þ is obtained similarly using the sequence information
of structural ðXSPj Þ and non-structural ðXNPj Þ proteins. Counts of
each amino acid in these proteins is multiplied by the respective
copy numbers of these proteins (Csp and Cnp):
XTOTj ¼ Csp(XSPj )þ Cnp(XNPj ), ð4:4Þ
where the indexation is over amino acids. Cnp is 1 for all viruses
studied here, while Csp is 240 for CHIKV [18], and 180 for
DENV/ZIKV [17]. The moles of amino acids per mole of virus
is then converted into grams of amino acid per mole of virus
(gAA mol
1
virus; G
X
j ), by multiplying X
TOT
j with the respective
molar mass (g mol21) of each amino acid (MX):
GXj ¼ XTOTj MXj , ð4:5Þ
where the indexation is over amino acids. Finally, the stoichi-
ometries of each amino acid in the VBOF is expressed as
rsif.royalsoci
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X
j ):
SXj ¼ 1000
XTOTj
Mv
 !
, ð4:6Þ
where the indexation is over amino acids. etypublishing.org
J.R.Soc.Interface
15:201801254.2.4. Calculating ATP requirement for amino acid polymerization
(mmol g1virus)
The polymerization of amino acid monomers requires approxi-
mately four ATP molecules per peptide bond [47], defined
here as the constant kATP (¼4) The overall moles of ATP
(ATOT) required to form the structural (ASP) and non-structural
(ANP) polyproteins are calculated from the respective amino
acid counts:
ASP ¼
X
j
XSPj  kATP
0
@
1
A kATP, ð4:7Þ
ANP ¼
X
j
XNPj  kATP
0
@
1
A kATP ð4:8Þ
and ATOT ¼ Csp(ASP)þ Cnp(ANP), ð4:9Þ
where the indexation is over amino acids. From ATOT, we cal-
culate the stoichiometry of ATP in the VBOF as millimoles per
gram of virus (SATP):
SATP ¼ 1000 A
TOT
Mv
 
: ð4:10Þ
As ATP is hydrolysed in this process, the water requirement
for polymerization (SH2O) is equal to that of ATP. The products
from the hydrolysis of ATP (ADP, Pi and H
þ) are also accounted
for in the VBOF (see equation (4.16)).4.2.5. Calculating pyrophosphate (PPi) liberation from nucleotide
polymerization (mmol g1virus)
The polymerization of nucleotide monomers to form the
RNA viral genome liberates a PPi molecule [47], defined
here as the constant kPPi (¼1). The overall moles of PPi (PTOT)
required to form the viral genome (PG) and replication
intermediates (PR) are calculated from the respective nucleotide
counts:
PG ¼
X
i
NGi  kPPi
 !
 kPPi, ð4:11Þ
PR ¼
X
i
NRi  kPPi
 !
 kPPi ð4:12Þ
and PTOT ¼ Cg(PG þ PR): ð4:13Þ
To convert this into the PPi stoichiometry in the VBOF as
millimoles per gram of virus (SPPi), we again use the overall
molar mass (g mol21) of one mole of virus:
SPPi ¼ 1000 P
TOT
Mv
 
: ð4:14Þ4.2.6. Calculating total viral molar mass
The total molar mass of the virus Mv is calculated from the total
mass of the genome and proteome components as
Mv ¼
X
i
GNi
 !
þ
X
j
GXj
0
@
1
A: ð4:15Þ4.2.7. Final construction of the VBOF
The left- and right-hand side terms of VBOF are based on
the above calculations of stoichiometric coefficients. The final
stoichiometry for the VBOF (pseudoreaction) is
SNi þ    þ SXj þ    þ SATP þ SH2O
! SADP þ SPi þ SHþ þ SPPi: ð4:16Þ
This pseudoreaction accounts for the virus’ biomass,
and the energy requirements associated with its production,
and can be incorporated into stoichiometric metabolic
models of the host to represent the presence of a virus in
that system.4.3. Construction of the human macrophage iAB-AMØ-
1410 metabolic model
The human macrophage metabolic model, iAB-AMØ-1410, was
constructed in a previous study [25]. This model was generated
using clinical transcriptomic datasets, collected from variant
patients’ alveolar macrophages, and using this to prune a set of
reactions from a previous human genome-scale stoichiometric
model of metabolism, RECON [48]. The objective function of
iAB-AMØ-1410 was generated in line with previous protocols
[44] using experimental and literature data to determine the
biomass maintenance of a human macrophage cell per hour [25].4.4. Integration of iAB-AMØ-1410 and Chikungunya,
Dengue and Zika viruses
The VBOFs for the three viruses (CHIKV, DENV and ZIKV) were
integrated into three separate instances of the ‘host’ macrophage
model (iAB-AMØ-1410) (original files are provided as electronic
supplementary material, file S7). In each case, the respective
VBOF was appended into the existing macrophage model, with
a lower flux bound of zero and an upper bound of infinity,
reflecting no upper constraints on this flux [49]. No other metab-
olites or reactions were added to any of the models. All of the
individual flux bounds of the model reactions were used as pre-
viously set [25], but any bounds set to 21000 or 1000 are
replaced with infinity, because the use of infinity, rather than
arbitrarily large values, is shown to be a more robust approach
to represent unbounded reactions in a linear programming
model [49]. We also confirmed that the use of arbitrary large
bounds (such as 21000/1000) instead of infinity does not
change the presented results qualitatively. A set of subprocesses,
derived from known aggregate subsystems [50], were appended
as metadata to each individual host–virus model and linked
with the pre-existing defined subsystems. A full description of
the subsystems and mapping of reactions into these are supplied
in electronic supplementary material, file S3. The used integrated
model is provided in a computer-readable (SBML) format with
the publication.4.5. Characterizing the stoichiometric differences
between host and virus
For both the host (iAB-AMØ-1410) and viruses (CHIKV,
DENV and ZIKV) we have pseudoreactions that capture the
metabolic requirements for the maintenance/production of
their respective biomass. By comparing these pseudoreaction
stoichiometries, we can quantify the differences in amino
acid and nucleotide requirements to fulfil the host or virus
objectives. To do so, we calculate the fold change in nucleotide
rsif.royalsocietypublishing.org
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stoichiometric coefficients against the sum of stoichiometries
of all metabolites present in the objective function (other
than ATP):
log2
ðPi SVi Þ=ðPk SVk Þ 
ðPi SHi Þ=ðPk SHk Þ 
 !
, ð4:17Þ
where indexation i is over nucleotides (or amino acids) and k is
over all biomass precursors, and the subscripts H and V indi-
cate the use of the host and virus biomass functions,
respectively. A positive value indicates a higher usage of
nucleotide (or amino acid) i by the virus than the host,
while a negative value indicates a lower usage. Soc.Interface
15:201801254.6. Comparison of host- and virus-optimized states
For all analyses, the generated host –virus integrated models
were optimized, and reaction fluxes predicted using the
linear optimization approach known as flux balance analysis
(FBA) [43]. Linear optimization is a mathematical technique
that optimizes a given function under a set of constraints
defined by mathematical inequalities. In the context of meta-
bolic models, the constraints correspond to limitations on
reaction fluxes, while the function to be optimized can be
defined as the flux in a specific reaction. While several bio-
logically plausible objective functions can be defined [51], a
standard approach is to define a pseudoreaction that
describes biomass production from its constituent parts,
and then optimize the flux to this reaction, as we have
done here. As the set of constraints includes constraints on
uptake reactions, this application of FBA results in the pre-
diction of optimal biomass production flux for a specific
uptake flux. In other words, FBA optimizes for biomass yield
from given substrates assumed to be present in the media. In
this work, we apply FBA to optimize a combined host–virus
metabolic system to satisfy either the host or virus objective
function (as described above) and study the resulting flux
predictions.
To simulate a virus-optimal state, the models are optimized
using the respective VBOFs of CHIKV, DENV and ZIKV viruses
as the objective function, while to simulate a host-optimal state,
the models are optimized using the existing biomass mainten-
ance reaction for the human macrophage as presented in [25].
Besides running linear optimization to find the optimal flux
sets under each scenario, we have also performed a flux varia-
bility analysis (FVA) [52], which provides flux ranges for each
reaction that still would allow attainment of given host/virus
optima. The FVA approach is shown to be more robust to
instabilities associated with prediction and comparison of a
single optimal flux sets [49]. For each reaction in the model
we compared the resulting flux ranges from FVA under host
and virus optimization, by evaluating the mean value of the
allowed flux range for each reaction (Ai) and then collating
the mean flux values for reactions associated with given sub-
processes (aggregated subsystems) as a percentage of total
flux through that process. More formally, we define the differ-
ential distribution of reaction flux for each subprocess (i)
between the host- and virus-optimized models in terms of a
fold change:
log2
ðPm AVi Þ=ðPk AVk Þ 
ðPm AHi Þ=ðPk AHk Þ 
 !
, ð4:18Þ
where the indexation k is over all reactions of the model, while
the indexation m is over reactions that belong to subprocess i.The superscript indicates the use of flux values from the host
(H )- and virus (V )-optimized models, respectively. A positive
value indicates a higher mean flux for subprocess i in the
virus- versus host-optimized model, while a negative value
indicates a lower mean flux.4.7. Reaction knockout and host-derived flux analyses
To find reactions that can preferentially alter virus-optimized
state of the model, we considered the effect of systematically
constraining individual reactions. Knockout analysis. Knockout
analysis considers the effect of systematically setting individ-
ual reaction fluxes to zero, and then attempting to maximize
for VBOF. The knockout optima for the virus production reac-
tion flux Zko is then compared to the original flux over this
reaction; Zwt. Host-derived enforcement. Host-derived enforce-
ment considers the effect of maintaining a metabolic system
in a host-optimized state while attempting to optimize the
model for VBOF. For this approach, we systematically set
individual lower and upper flux bounds of individual reac-
tions to a specific flux range. For each reaction, this range
(1r) is derived from the corresponding minimum (F2) and
maximum (Fþ) flux values for that reaction obtained from the
FVA using the host (H ) and virus (V ) optimization (as described
above). The range (1r) is bounded by minimum (12) and maxi-
mum (1þ) flux values, which are given by the following
conditional arguments:
if FþH . F
þ
V , F

H  FV
then 1þ ¼ FþH
1 ¼ FþH 
FþH  FþV
2
 
, ð4:19Þ
if FH , F

V ,F
þ
H  FþV
then 1 ¼ FH
1þ ¼ FH 
FH  FV
2
 
ð4:20Þ
and if FH . F

V ,F
þ
H , F
þ
V
then 1 ¼ FH
1þ ¼ FþH ð4:21Þ
These calculated flux ranges for each individual reaction are
then used to constrain the model, and the model is optimized for
the VBOF. The resulting optima for the virus production reaction
flux, Ze is recorded and compared to the original optimal
value, Zwt.
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